Home  >  News
Eppen_epTIPS_Dec2025
you can get e-magazine links on WhatsApp. Click here
News
  VectorY Therapeutics receives US FDA clearance to proceed with PIONEER-ALS phase 1/2 clinical trial of VTx-002,   December 05, 2025
  iOnctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition,   December 05, 2025
  AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH,   December 05, 2025
  Jazz Pharma to present pivotal phase 3 results of Ziihera combinations in first-line HER2-positive locally advanced or metastatic GEA at 2026 ASCO GI symposium,   December 04, 2025
  China NMPA approves Antengene’ IND application for phase Ib/II study of ATG-022 in combo with Keytruda± chemotherapy,   December 03, 2025
  Bayer initiates phase III study SUNFLOWER with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia,   December 03, 2025
  GSK to present new data from its haematology portfolio at the 67th ASH Annual Meeting and Exposition,   December 03, 2025
  Bristol Myers Squibb data at ASH 2025 showcase potential of haematology pipeline and build momentum for next generation portfolio,   December 02, 2025
  Merck showcases data for Alzheimer’s disease candidates MK-2214 and MK-1167 at CTAD 2025,   December 02, 2025
  Ideaya Biosciences receives US FDA clearance to initiate phase 1 trial to evaluate IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC targeting multiple solid tumour types,   December 02, 2025
  Generate:Biomedicines to begin global phase 3 studies of GB-0895, a long-acting anti-TSLP antibody for severe asthma engineered with AI,   December 02, 2025
  Gan & Lee Pharmaceuticals begins GRADUAL-3 phase 3 study of first Chinese once-monthly GLP-1 RA for weight management,   December 01, 2025
  InnoCare begins patient dosing in global phase II trial of TYK2 inhibitor, Soficitinib to treat prurigonodularis,   December 01, 2025
  Renalys Pharma reports positive results from phase III study of sparsentan in Japanese patients with IgA nephropathy,   November 28, 2025
  Chugai Pharma announces results from phase I/II study in Japan to evaluate the efficacy and safety of Port Delivery System with Ranibizumab in patients with nAMD & DME,   November 27, 2025
  Novo Nordisk announces phase 2 clinical trial results of amycretin in people with type 2 diabetes,   November 27, 2025
  NeuroSense receives US FDA clearance to begin pivotal phase 3 trial for PrimeC in ALS,   November 26, 2025
  Pin Therapeutics begins patient dosing in phase 1 clinical trial of CK1a degrader PIN-5018,   November 25, 2025
  Merck to present new data across multiple hematologic malignancies at ASH Annual Meeting in Orlando, from December 6-9,   November 25, 2025
  Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention,   November 25, 2025

 Back
 
PharmaTech_LabTech_Expo_2025
AUTOMA+_2025
Ana_Lab_India_2026
PharmaCore_India_2026
×
                                                                                                                               
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram